The mission of the Penn ADCC is to increase research and education on AD, related dementias, normal brain aging and mild cognitive impairment (MCI), as well as support development of better diagnostics and preventions/treatments for AD and related disorders. The Penn ADCC provides research training, stimulates new research on normal aging and neurodegenerative dementias as well as development of novel techniques to address the challenges of conducting research on these disorders. The Penn ADCC is a highly interdisciplinary and seamlessly integrated Center with 5 Cores that collaborate extensively with other investigators at and beyond Penn, including the NIH/NIA funded AD Centers (ADCs), NACC, AD Cooperative Study (ADCS), AD Education and Referral (ADEAR) Center, the AD Neuroimaging Initiative (ADNI), AD Genetics Consortium (ADGC) and other NIH/public/private initiatives on AD, related disorders and healthy brain aging.
The Aims of the Penn ADCC are implemented through: 1) Administrative Core A to oversee and direct the activities of the ADCC;2) Clinical Core B to recruit, follow and study subjects with AD, MCI or related disorders and controls;3) Data Management and Biostatistics Core C to provide data management and biostatistical expertise;4) Neuropathology, Genetics and Biomarker Core D to establish postmortem diagnoses on ADCC subjects, and bank CNS tissues, DNA and biofluids from ADCC subjects for diagnostic studies and research;5) Education, Recruitment and Retention Core E to develop, implement and monitor recruitment and retention programs and ensure that the ADCC team as well as patients and families have up to- date knowledge of AD and related diseases;6) Pilot Grant Program to stimulate novel research on AD and related disorders;7) Collaborations with other investigators at and beyond Penn to improve diagnostics and treatments for AD and related disorders as well as increase understanding of these conditions and promote healthy brain aging. In summary, the Penn ADCC contributes to US and global strategies to meet the worldwide challenges of rapidly aging populations and the epidemic of AD and related disorders. In alignment with NIA RFA-AG-11- 005, the Penn ADCC accomplishes its mission in the renewal period through research on AD and related disorders as well as normal aging and through education to increase understanding of these disorders and their global effects.

Public Health Relevance

of the Penn ADCC is that it challenges/re-defines current clinical practice paradigms and research on AD and related disorders as well as MCI and normal aging by utilizing novel concepts and approaches to achieve the goals of this ADCC which are to increase research and education on AD, related dementias, normal brain aging and MCI, as well as support development of better diagnostics and preventions/treatments for AD and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG010124-21
Application #
8174032
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
1997-07-15
Project End
2016-06-30
Budget Start
2011-08-01
Budget End
2012-06-30
Support Year
21
Fiscal Year
2011
Total Cost
$1,463,474
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Largent, Emily A; Karlawish, Jason; Grill, Joshua D (2018) Study partners: essential collaborators in discovering treatments for Alzheimer's disease. Alzheimers Res Ther 10:101
Bezdicek, Ondrej; ?ervenková, Markéta; Moore, Tyler M et al. (2018) Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison. Assessment :1073191118778896
Irwin, David J; McMillan, Corey T; Xie, Sharon X et al. (2018) Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain 141:288-301
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Racine, Annie M; Brickhouse, Michael; Wolk, David A et al. (2018) The personalized Alzheimer's disease cortical thickness index predicts likely pathology and clinical progression in mild cognitive impairment. Alzheimers Dement (Amst) 10:301-310
Phillips, Jeffrey S; Da Re, Fulvio; Dratch, Laynie et al. (2018) Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiol Aging 63:75-87
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 720 publications